Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CC-122 + Spebrutinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CC-122||Avadomide||Avadomide (CC-122) is an immunomodulatory drug analog that targets Cereblon and promotes degradation of several proteins, including Ikaros and Aiolos, leading to decreased B-cell proliferation and decreased tumor angiogenesis (Blood Dec 2014, 124 (21) 3500).|
|Spebrutinib||AVL-292|CC-292||BTK inhibitor 22||Spebrutinib (CC-292) is a covalent inhibitor of Btk that decreases Btk kinase activity and activation of downstream signaling, resulting in reduced B-cell proliferation (PMID: 24518207).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02031419||Phase I||CC-122 + Spebrutinib Onatasertib + Spebrutinib CC-122 + Onatasertib Rituximab||Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma||Active, not recruiting|